Anticoagulation UK

28 February 2019

Rivaroxaban (Xarelto) has been accepted by the Scottish Medicines Agency for restricted use within Scotland for the following indication.

Indication under review: Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with:

- coronary artery disease, or

symptomatic peripheral artery disease at high risk of ischaemic events.

For full details click here